Withings Health Solutions has announced that its BPM Pro 2 blood pressure monitor has received FDA clearance, marking a major advancement in remote patient monitoring. The device, the first of its kind, features cellular connectivity and automates several aspects of clinical workflows, making it easier for healthcare teams to manage patients remotely.
The BPM Pro 2 is designed to measure blood pressure and pulse rate in adults with arm circumferences ranging from 9 to 17 inches, or 16 to 20 inches. According to Withings, the monitor offers patients the ability to take more accurate blood pressure readings at home, under optimal conditions, and provides valuable data to care teams.
One of the key features of the BPM Pro 2 is its new Patient Insights tool, which enhances readings by asking users about their symptoms, medication adherence, and other relevant factors. This allows clinicians to gain a deeper understanding of each patient’s condition, while also reducing the workload for healthcare professionals.
By automating tasks like symptom tracking, measurement reminders, and prompts, the BPM Pro 2 minimizes the need for manual patient outreach. This enables healthcare providers to focus more on delivering quality care. The device also includes features like personalized health nudges, an easy-to-use design, and seamless connectivity for both patients and care teams.
Antoine Robiliard, VP of Withings Health Solutions, expressed excitement about the FDA clearance, stating, “We are thrilled that BPM Pro 2 is now FDA-cleared. This device represents a significant leap forward in remote patient monitoring, providing not only precise blood pressure and pulse rate measurements but also empowering care teams with real-time insights and enhanced patient engagement tools.”
Withings also highlighted that the BPM Pro 2 was recently recognized as a CES 2025 Innovation Awards Honoree, further cementing the company’s commitment to creating solutions that streamline healthcare workflows and improve the quality of remote care.
Related topics:
- Australians Spend Over $1.2 Billion Each Year on High Blood Pressure Treatment, Analysis Reveals
- Lower Cholesterol And Blood Sugar with £1.29 Drink Available at Home Bargains
- Outcomes of Sacubitril/Valsartan Compared to Enalapril in Heart Failure Patients with Hypotension